Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-29
2011-03-29
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S567000, C514S649000
Reexamination Certificate
active
07915262
ABSTRACT:
A composition containing SLV308 or its N-oxide, or at least one pharmacologically acceptable salt thereof:and L-DOPA or at least one pharmacologically acceptable salt thereof, for simultaneous, separate or sequential use in the treatment of disorders requiring recovery of dopaminergic function using this composition, including Parkinson's disease and restless leg syndrome.
REFERENCES:
patent: 2004/0077631 (2004-04-01), Van Aar et al.
patent: 2005/0234389 (2005-10-01), Bouwstra et al.
patent: 0 908 458 (1999-04-01), None
patent: 0 189 612 (2006-08-01), None
patent: WO 97/36893 (1997-10-01), None
patent: WO 00/29397 (2000-05-01), None
patent: WO 01/74365 (2001-10-01), None
patent: WO 02/066449 (2002-08-01), None
patent: WO 2006/032202 (2006-03-01), None
patent: WO 2006/032202 (2006-03-01), None
patent: WO 2006/087369 (2006-08-01), None
patent: WO 2007/023141 (2007-03-01), None
“Bifeprunox—Atypical Antipsychotic Drug,” Drug Development Technology, pp. 1-3, 2007, www.drugdevelopment-technology.com/projects/bifeprunox/.
“Solvay Announces New Drug Plans for Schizophrenia,” Schizophernia Daily New Blog, pp. 1-4 (2004), www.schizophrenia.com/sznews/archives/000573.html.
(XP-001061442) Johnston, L.C. et al., “134P: The Novel Dopamine D2 Receptor Partial Agonist, SLV-308, Reverses Motor Disability in MPTO-Lesioned Common Marmosets (CALLITHRIXJACCHUS),” British Journal of Pharmacology, vol. 133, No. 2 (2001).
(XP-001061489) Feenstra, R. et al., “Antiparkinsonian Antidepressant Anxiolytic Dopamine D2Partial Agonist 5-HT1AAgonist,” Drugs of the Future, vol. 26, No. 2, pp. 128-132 (2001).
(XP-001197381) McCreary, A.C., et al., “SLV308: A Novel Antiparkinsonian Agent With Antidepressant and Anxiolytic Efficacy,” Abstracts of the Society for Neuroscience (2001).
(XP-002412435) Hesselink, M. et al., “SLV308, a molecule combining potent partial dopamine D2 receptor agonism with serotonin 5-HT1A receptor agonist: in vitro and in vivo neuro chemistry,” 31stAnnual Meeting of the Society for Neuroscience (Nov. 10-15, 2001).
(XP-002412436) Johnston, L.C. et al., SLV308: Antiparkinsonian effects in the MPTP-treated common marmoset (Callithrix jacchus), 31stAnnual Meeting of the Society for Neuroscience (Nov. 10-15, 2001).
(XP-002412438) WPI/Thomson, “English language abstract of WO 2006/032202”.
Allen, Richard P. et al. “A Review of Clinical and Pathophysiologic Features,” Journal of Clinical Neurophysiology, vol. 18, No. 2, pp. 128-147 (2001).
Allen, Richard P. et al., “Augmentation of the Restless Legs Syndrome With Carbidopa/Levedopa,” Sleep, vol. 19, No. 3, pp. 205-213 (1996).
Bara-Jimenez et al., “Effects of Serotonin 5-HT1A Agonist in Advanced Parkinson's Disease,” Movement Disorders, vol. 20, No. 8, pp. 932-936 (2005).
Bennett, Jr., James P., et al., “Pramipexole—A new dopamine agonist for the treatment of Parkinson's Disease,” Journal of Neurological Sciences, vol. 163, pp. 25-31 (1999).
Berendsen, et al., “Selective Activation of 5HT1A Receptors Induces Lower Lip Retraction in the Rat,” Pharmacology Biochemistry & Behavior, vol. 33, pp. 821-827, 1989.
Bibbiani, Francesco et al., “Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models,” Neurology, vol. 57, pp. 1829-1834 (2001).
Bickel, M.H., “The Pharmacology and Biochemistry of N-Oxides,” Pharmacological Reviews, vol. 21, No. 4, pp. 325-355, 1969.
Blandini, Fabio, et al., “Functional Changes of the Basal Ganglia Circuitry in Parkinson's Disease,” Progress in Neurobiology, vol. 62, pp. 63-88 (2000).
Chesson, Jr., Andrew L., et al., “Practice Parameters for the Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder,” Sleep, vol. 22, No. 7, pp. 961-968 (1999).
Christoffersen, Curt L., et al., “Reversal of Haloperiodol-Induced Extrapyramidal Side Effects in Cebus Monkeys by 8-Hydroxy-2-(di-n-propylamino)tetralin and Its Enantiomers,” American College of Neuropsychopharmacology, vol. 18, No. 5, pp. 399-402 (1998).
Copending U.S. Appl. No. 10/920,361, filed Aug. 18, 2004.
Copending U.S. Appl. No. 10/920,386, filed Aug. 18, 2004.
Copending U.S. Appl. No. 11/354,652, filed Feb. 16, 2006.
Copending U.S. Appl. No. 11/727,173, filed Mar. 23, 2007.
Copending U.S. Appl. No. 11/743,049, filed May 1, 2007.
Copending U.S. Appl. No. 11/762,239, filed Jun. 13, 2007.
Copending U.S. Appl. No. 11/847,197, filed Aug. 29, 2007.
Copending U.S. Appl. No. 11/847,458, filed Aug. 30, 2007.
Costall et al., “Differential actions of typical and atypical neuroleptic agents on two behavioural effects of apomorphine in the mouse,” Proceedings of the B.P.S., pp. 381-381, 1978.
Creese et al., “3H-Spiroperidol Labels Dopamine Receptors in Pituitary and Brain,” European Journal of Pharmacology, 46, pp. 377-381, 1977.
Earley, Christopher J., et al., “Movements During Sleep: Pergolide and Carbidopa/Levedopa Treatment of the Restless Legs Syndrome and Periodic Leg Movements in Sleep in a Consecutive Series of Patients,” Sleep, vol. 19, No. 10, pp. 801-810 (1996).
European International Search Report and Written Opinion for PCT/EP2007/055955, filed Jun. 15, 2007 mailed Sep. 10, 2007.
Feenstra, Rolf W., et al., “New 1-Aryl-4-(biarylmethylene) piperazines as Potential Atypical Antipsychotics Sharing Dopamine Ds-Receptor and Serotonin 5-HT1A-Receptor Affinities,” Bioorganic & Medicinal Chemistry Letters 11, pp. 2345-2349 (2001).
Feenstra, Rolf W., et al., “New Approaches for Psychosis Treatment: Design, Synthesis and SAR of Ligands Binding to Dopamine-D2- and Serotonin 5-HT1AReceptors,” Drugs of the Future, vol. 27, Suppl. A, p. 226 (P237), XVIIthInternational Symposium on Medicinal Chemistry (2002).
Fleischhacker, “Clozapine: A Comparison With Other Novel Antipsychotics,” J. Clin Psychiatry, vol. 60, No. 12, 1999, pp. 30-34.
Gozlan, et al., “Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT,” Nature, vol. 305, pp. 140-142, 1983.
Haleblian et al., “Pharmaceutical Applications of Polymorphism,” Journal of Pharmaceuticals Sciences, vol. 58, No. 8, 1969, pp. 911-929.
Hening, Wayne A., et al., “Dyskinesias While Awake and Periodic Movements in Sleep in Restless Legs Syndrome: Treatment with Opioids,” Neurology, vol. 36, pp. 1363-1366 (1986).
Hening, Wayne et al., “The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder,” Sleep, vol. 22, No. 7, pp. 970-999 (1999).
Hesselink, M.B., et al., “DU127090, SLV308 and SLV318: Characterization of a Chemically Related Class of Partial Dopamine Agonists with Varying Degrees of 5-HT1A Agonism,” EFNS European Journal of Neurology, vol. 10 (Suppl. 1), pp. 125-204 (2003).
Hornykiewicz, Oleh, “Dopamine (3-Hydroxytyramine) and Brain Function,” Pharmaceutical Reviews, vol. 18, No. 2, pp. 925-964 (1966).
Jankovic, Joseph, “Natural Course and Limitations of Levodopa Therapy,” Neurology, vol. 43, No. 2, Supplement 1, pp. S1-14 thru S1-17 (1993).
Jenner, Peter, “Pharmacology of Dopamine Agonists in the Treatment of Parkinson's Disease,” Neurology vol. 58 (Suppl. 1), pp. S1-S8 (2002).
Johnston, L.C., et al., “Association Between Instrinsic Activity and the Antiparkinsonian Effects of a Novel Dopamine D2 Agonist series in the 1-methyl-4pheny1-1,2,3,6-tetrahydeopyridine Treated Primate Model of Parkinson's Disease,” EFNS European Journal of Neurology, vol. 10 (Suppl. 1), pp. 169-170 (2003).
Jost, W.H., et al., “Efficacy and Tolerability of Stalevo® in Patients with Parkinson's Disease Experiencing Wearing-off,” Akt Neurol, vol. 32, Supplement 6, pp. S318-S325 (2005).
Kannari, et al., “Tandospirone Citrate, a Selective 5-HT1AAgonist, Alleviates L-DOPA-Induced Dyskinesia
McCreary Andrew C
Tulp Martinus Th. M.
Van Scharrenburg Gustaaf J. M.
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Kim Jennifer M
Solvay Pharmaceuticals B.V.
LandOfFree
Combination preparations comprising SLV308 and a dopamine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination preparations comprising SLV308 and a dopamine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination preparations comprising SLV308 and a dopamine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2678429